JATT Acquisition (JATT) Competitors $2.03 -0.02 (-0.98%) As of 08/26/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JATT vs. IPA, ALTS, ZURA, TARA, AVTX, ZNTL, CRBP, SAVA, SPRO, and HLVXShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include ImmunoPrecise Antibodies (IPA), ALT5 Sigma (ALTS), Zura Bio (ZURA), Protara Therapeutics (TARA), Avalo Therapeutics (AVTX), Zentalis Pharmaceuticals (ZNTL), Corbus Pharmaceuticals (CRBP), Cassava Sciences (SAVA), Spero Therapeutics (SPRO), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Its Competitors ImmunoPrecise Antibodies ALT5 Sigma Zura Bio Protara Therapeutics Avalo Therapeutics Zentalis Pharmaceuticals Corbus Pharmaceuticals Cassava Sciences Spero Therapeutics HilleVax ImmunoPrecise Antibodies (NASDAQ:IPA) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk. Which has better earnings & valuation, IPA or JATT? JATT Acquisition has lower revenue, but higher earnings than ImmunoPrecise Antibodies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$17.59M6.53-$21.69M-$0.68-3.66JATT AcquisitionN/AN/A$6.85MN/AN/A Do analysts prefer IPA or JATT? ImmunoPrecise Antibodies presently has a consensus price target of $4.00, indicating a potential upside of 60.64%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher possible upside, equities analysts plainly believe ImmunoPrecise Antibodies is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IPA or JATT more profitable? JATT Acquisition has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -122.10%. ImmunoPrecise Antibodies' return on equity of -40.62% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-122.10% -40.62% -22.19% JATT Acquisition N/A -49.58%2.84% Do insiders and institutionals believe in IPA or JATT? 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Comparatively, 20.0% of JATT Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor IPA or JATT? In the previous week, ImmunoPrecise Antibodies had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for ImmunoPrecise Antibodies and 0 mentions for JATT Acquisition. ImmunoPrecise Antibodies' average media sentiment score of 0.77 beat JATT Acquisition's score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media. Company Overall Sentiment ImmunoPrecise Antibodies Positive JATT Acquisition Neutral SummaryImmunoPrecise Antibodies beats JATT Acquisition on 7 of the 12 factors compared between the two stocks. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$35.02M$282.43M$5.76B$21.29BDividend YieldN/AN/A3.95%3.53%P/E RatioN/AN/A31.3129.36Price / SalesN/A538.68461.3052.76Price / Cash27.0822.4437.7623.64Price / Book-3.8310.1710.025.38Net Income$6.85M-$115.81M$3.27B$996.59M7 Day Performance16.00%2.26%3.17%3.12%1 Month Performance23.78%-4.93%4.34%2.98%1 Year Performance-52.35%-12.97%44.11%12.83% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$2.03-1.0%N/A-49.6%$35.02MN/A0.003High Trading VolumeIPAImmunoPrecise Antibodies2.1184 of 5 stars$2.89+12.5%$4.00+38.4%+245.8%$118.62M$17.59M-4.2580ALTSALT5 Sigma0.3556 of 5 stars$5.89+7.5%N/A+178.5%$118.42M$12.53M0.00170Gap UpZURAZura Bio3.0636 of 5 stars$1.75+1.2%$14.00+700.0%-49.3%$118.29MN/A-2.503TARAProtara Therapeutics1.7273 of 5 stars$3.03-0.7%$19.60+546.9%+56.8%$117.68MN/A-1.8730AVTXAvalo Therapeutics3.3583 of 5 stars$9.22+3.6%$30.00+225.4%-12.0%$116.99M$440K0.0040News CoveragePositive NewsZNTLZentalis Pharmaceuticals1.9892 of 5 stars$1.64+3.1%$8.20+400.0%-40.3%$114.69M$67.43M-0.73160CRBPCorbus Pharmaceuticals4.4043 of 5 stars$9.22+1.0%$49.00+431.5%-81.7%$111.89MN/A-1.9440Positive NewsSAVACassava Sciences1.7291 of 5 stars$2.14-2.3%$2.00-6.5%-92.0%$105.79MN/A-0.8430Positive NewsSPROSpero Therapeutics4.0686 of 5 stars$1.83-0.5%$5.00+173.2%+43.5%$103.55M$47.98M-1.87150HLVXHilleVax1.7209 of 5 stars$2.07+0.5%$2.00-3.4%+7.8%$103.29MN/A-1.4520Positive News Related Companies and Tools Related Companies IPA Alternatives ALTS Alternatives ZURA Alternatives TARA Alternatives AVTX Alternatives ZNTL Alternatives CRBP Alternatives SAVA Alternatives SPRO Alternatives HLVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access